{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:15:53Z","timestamp":1791357353132,"version":"4.3.1"},"reference-count":61,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicines"],"abstract":"<jats:p>Background: Besides its well-known role as a peripheral chemical mediator of immune, vascular, and cellular responses, histamine plays major roles in the central nervous system, particularly in the mediation of arousal and cognition-enhancement. These central effects are mediated by the histamine-3 auto receptors, the modulation of which is thought to be beneficial for the treatment of disorders that impair cognition or manifest with excessive daytime sleepiness. Methods: A database search of PubMed, Google Scholar, and clinicaltrials.gov was performed in June 2020. Full-text articles were screened and reviewed to provide an update on pitolisant and other histamine-3 receptor antagonists. Results: A new class of drugs\u2014histamine-3 receptor antagonists\u2014has emerged with the approval of pitolisant for the treatment of narcolepsy with or without cataplexy. At the recommended dose, pitolisant is well tolerated and effective. It has also been evaluated for potential therapeutic benefit in Parkinson disease, epilepsy, attention deficit hyperactivity disorder, Alzheimer\u2019s disease, and dementia. Limited studies have shown pitolisant to lack abuse potential which will be a major advantage over existing drug options for narcolepsy. Several histamine-3 receptor antagonists are currently in development for a variety of clinical indications. Conclusions: Although limited clinical studies have been conducted on this new class of drugs, the reviewed literature showed promising results for future additions to the clinical indications of pitolisant, and the expansion of the list of approved drugs in this class for a variety of indications.<\/jats:p>","DOI":"10.3390\/medicines7090055","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T08:53:43Z","timestamp":1598950423000},"page":"55","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pitolisant and Other Histamine-3 Receptor Antagonists\u2014An Update on Therapeutic Potentials and Clinical Prospects"],"prefix":"10.3390","volume":"7","author":[{"given":"Victoria","family":"Harwell","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Campbell University, Buies Creek, NC 27501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3160-1824","authenticated-orcid":false,"given":"Pius","family":"Fasinu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Campbell University, Buies Creek, NC 27501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/j.1365-2222.2009.03374.x","article-title":"Histamine, histamine receptors and their role in immune pathology","volume":"39","author":"Jutel","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00212757","article-title":"Behavioural effects of histamine and its antagonists: A review","volume":"95","author":"White","year":"1988","journal-title":"Psychopharmacology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2006.06.008","article-title":"The physiological and pathophysiological roles of neuronal histamine: An insight from human positron emission tomography studies","volume":"113","author":"Yanai","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_4","first-page":"427","article-title":"Receptors mediating some actions of histamine","volume":"27","author":"Ash","year":"1966","journal-title":"Br. J. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1038\/sj.bjp.0706440","article-title":"Histamine and its receptors","volume":"147","author":"Parsons","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd1631","article-title":"The histamine H 3 receptor: From gene cloning to H 3 receptor drugs","volume":"4","author":"Leurs","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0006-8993(90)91240-H","article-title":"Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates","volume":"526","author":"Pollard","year":"1990","journal-title":"Brain Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.tips.2004.10.003","article-title":"The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders","volume":"25","author":"Passani","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0166-4328(01)00216-9","article-title":"Histamine H3-receptor antagonism improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task","volume":"124","author":"Orsetti","year":"2001","journal-title":"Behav. Brain Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Leurs, R., Vollinga, R.C., and Timmerman, H. (1995). The medicinal chemistry and therapeutic potentials of ligands of the histamine H 3 receptor. Progress in Drug Research\/Fortschritte der Arzneimittelforschung\/Progr\u00e8s des Recherches Pharmaceutiques, Birkh\u00e4user.","DOI":"10.1007\/978-3-0348-7164-8_4"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/bjp.2008.147","article-title":"The histamine H3 receptor: An attractive target for the treatment of cognitive disorders","volume":"154","author":"Esbenshade","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1021\/jm100064d","article-title":"Histamine H3 receptor as a drug discovery target","volume":"54","author":"Berlin","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1124\/mol.116.104752","article-title":"The histamine H3 receptor: Structure, pharmacology, and function","volume":"90","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0928-0987(01)00106-3","article-title":"Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists","volume":"13","author":"Meier","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1021\/jm990952j","article-title":"Design, synthesis, and structure\u2212activity relationships of novel non-imidazole histamine H3 receptor antagonists","volume":"43","author":"Linney","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1021\/jm000966l","article-title":"Novel Histamine H3-Receptor Antagonists with Carbonyl-Substituted 4-(3-(Phenoxy) propyl)-1 H-imidazole Structures like Ciproxifan and Related Compounds","volume":"43","author":"Stark","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1021\/jm8003834","article-title":"Synthesis, structure\u2014Activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists","volume":"51","author":"Nagase","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1021\/ci200435b","article-title":"Structure-based prediction of subtype selectivity of histamine H3 receptor selective antagonists in clinical trials","volume":"51","author":"Kim","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_20","first-page":"245","article-title":"Physiology of REM sleep, cataplexy, and sleep paralysis","volume":"67","author":"Hishikawa","year":"1995","journal-title":"Adv. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","article-title":"Narcolepsy with cataplexy","volume":"369","author":"Dauvilliers","year":"2007","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Thompson, M.D., Sakurai, T., Rainero, I., Maj, M.C., and Kukkonen, J.P. (2017). Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics. Pharmaceuticals, 10.","DOI":"10.3390\/ph10040079"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.smrv.2018.09.006","article-title":"Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy","volume":"43","author":"Szabo","year":"2019","journal-title":"Sleep Med. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.106.111039","article-title":"BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist\/antagonist at the human histamine H3 receptor: Preclinical pharmacology","volume":"320","author":"Ligneau","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","article-title":"An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin\u2212\/\u2212 mice and patients","volume":"30","author":"Lin","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","article-title":"Pitolisant versus placebo or modafinil in patients with narcolepsy: A double-blind, randomised trial","volume":"12","author":"Dauvilliers","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_28","unstructured":"European Medicines Agency (2020, July 11). Wakix Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/wakix-epar-public-assessment-report_en.pdf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"zsz174","DOI":"10.1093\/sleep\/zsz174","article-title":"Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study","volume":"42","author":"Dauvilliers","year":"2019","journal-title":"Sleep"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1474-4422(16)30333-7","article-title":"Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: A randomised, double-blind, placebo-controlled trial","volume":"16","author":"Szakacs","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1528-1157.1995.tb00996.x","article-title":"Histamine in cerebrospinal fluid of children with febrile convulsions","volume":"36","author":"Kiviranta","year":"1995","journal-title":"Epilepsia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.0013-9580.2004.19303.x","article-title":"Development of amygdaloid kindling in histidine decarboxylase deficient and histamine H1 receptor-deficient mice","volume":"45","author":"Hirai","year":"2004","journal-title":"Epilepsia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejmech.2014.03.014","article-title":"Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties","volume":"77","author":"Sadek","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.yebeh.2013.03.018","article-title":"Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: Dose-dependent effects in the human photosensitivity model","volume":"28","author":"Parain","year":"2013","journal-title":"Epilepsy Behav."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/WNF.0000000000000159","article-title":"Exploratory Phase II Trial to Evaluate the Safety and the Antiepileptic Effect of Pitolisant (BF2.649) in Refractory Partial Seizures, Given as Adjunctive Treatment During 3 Months","volume":"39","author":"Dutilleul","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1513\/pats.200708-119MG","article-title":"Adherence to continuous positive airway pressure therapy: The challenge to effective treatment","volume":"5","author":"Weaver","year":"2008","journal-title":"Proc. Am. Thorac. Soc."},{"key":"ref_37","first-page":"245","article-title":"Adherence to continuous positive airway pressure treatment for obstructive sleep apnea: Implications for future interventions","volume":"131","author":"Weaver","year":"2010","journal-title":"Indian J. Med. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1164\/rccm.201907-1284OC","article-title":"Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial","volume":"201","author":"Dauvilliers","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1164\/rccm.202001-0104ED","article-title":"Treat the Symptom, Not the Cause? Pitolisant for Sleepiness in Obstructive Sleep Apnea","volume":"201","author":"Trotti","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11910-996-0041-8","article-title":"Excessive daytime sleepiness and unintended sleep in Parkinson\u2019s disease","volume":"6","author":"Rye","year":"2006","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/brain\/awm090","article-title":"Hypocretin (orexin) loss in Parkinson\u2019s disease","volume":"130","author":"Fronczek","year":"2007","journal-title":"Brain"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.sleep.2020.01.020","article-title":"Pitolisant for treating narcolepsy comorbid with Parkinson\u2019s disease","volume":"69","author":"Liguori","year":"2020","journal-title":"Sleep Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WNF.0b013e318246879d","article-title":"Pitolisant, an inverse agonist of the histamine H3 receptor: An alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness","volume":"35","author":"Inocente","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"A309","DOI":"10.1093\/sleep\/zsz067.769","article-title":"0771 Pitolisant Is a Safe and Effective Treatment for Children with Prader-willi Syndrome (pws)","volume":"42","author":"Pullen","year":"2019","journal-title":"Sleep"},{"key":"ref_45","first-page":"166","article-title":"Cognitive Improvements in Children with Prader-Willi Syndrome Following Pitolisant Treatment\u2014Patient Reports","volume":"24","author":"Pullen","year":"2019","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.sleep.2019.10.024","article-title":"Pharmacokinetics of pitolisant in children and adolescents with narcolepsy","volume":"66","author":"Lecendreux","year":"2020","journal-title":"Sleep Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1006\/nbdi.2001.0413","article-title":"Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson\u2019s disease","volume":"8","author":"Anichtchik","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"zsz252","DOI":"10.1093\/sleep\/zsz252","article-title":"Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist\/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy","volume":"43","author":"Setnik","year":"2020","journal-title":"Sleep"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1567205010666131212110148","article-title":"A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer\u2019s disease","volume":"11","author":"Grove","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/cns.12279","article-title":"Procognitive properties of drugs with single and multitargeting H3 receptor antagonist activities","volume":"20","author":"Nikolic","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/bcp.12281","article-title":"The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers","volume":"77","author":"Othman","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/11631990-000000000-00000","article-title":"Randomized Clinical Study Investigators. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder","volume":"26","author":"Weisler","year":"2012","journal-title":"CNS Drugs"},{"key":"ref_53","unstructured":"U.S. National Library of Med (2020, June 15). A Safety and Effectiveness Study of JNJ-31001074 in Adults with Attention-Deficit\/Hyperactivity Disorder, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00566449?term=JNJ-31001074&draw=2&rank=4."},{"key":"ref_54","unstructured":"U.S. National Library of Med (2020, June 15). BEN-2001 in Parkinson Disease Patients with Excessive Daytime Sleepiness (CASPAR), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03194217?term=JNJ-31001074&draw=2&rank=9."},{"key":"ref_55","unstructured":"U.S. National Library of Med (2020, June 15). A Study of GSK189254 and Duloxetine in the Electrical Hyperalgesia Model of Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00387413?term=GSK189254&draw=2&rank=2."},{"key":"ref_56","unstructured":"U.S. National Library of Med (2020, June 15). Allergen Challenge Chamber Study with Single Dose Intranasal GSK1004723 Compared with Placebo, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00824356?term=GSK1004723&draw=2&rank=1."},{"key":"ref_57","unstructured":"U.S. National Library of Med (2020, June 15). Allergen Challenge Chamber Study with Single Dose Oral GSK835726 Compared with Placebo, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00851344?term=GSK835726&draw=2&rank=1."},{"key":"ref_58","unstructured":"U.S. National Library of Med (2020, June 15). A Study to Test a New Decongestant in Patients with Allergic Rhinitis Following a Nasal Allergen Challenge, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00562120?term=PF-03654746&draw=2&rank=7."},{"key":"ref_59","unstructured":"U.S. National Library of Med (2020, June 15). Add on Treatment for Cognitive Deficits in Schizophrenia, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01346163?term=PF-03654746&draw=2&rank=4."},{"key":"ref_60","unstructured":"U.S. National Library of Med (2020, June 15). Effect of Different Doses of SAR110894 on Cognition in Patients with Mild to Moderate Alzheimer\u2019s Disease on Donepezil, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01266525?term=SAR110894&draw=2&rank=1."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lehert, P., and Szoeke, C. (2020). Comparison of modafinil and pitolisant in narcolepsy: A non-inferiority meta-analytical approach. Drugs Context, 9.","DOI":"10.7573\/dic.2020-6-2"}],"container-title":["Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6320\/7\/9\/55\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:05:30Z","timestamp":1760177130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6320\/7\/9\/55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":61,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["medicines7090055"],"URL":"https:\/\/doi.org\/10.3390\/medicines7090055","relation":{},"ISSN":["2305-6320"],"issn-type":[{"value":"2305-6320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}